ARTICLE
23 December 2020

Health Canada Releases Updated Warnings About Elmiron Related Vision Loss

SL
Siskinds LLP

Contributor

Since 1937, Siskinds has been that firm of specialists serving individuals, families and businesses in southwestern Ontario and Canada from our offices in London, Sarnia and Quebec City. We’ve grown as the world around us has evolved. Today, we are a team of over 230 lawyers and support staff covering personal, business, personal injury and class action law and over 25 specialized practice areas.
Health Canada released a Dear Health Professional Letter on December 15, 2020 to advise healthcare professionals, including urologists, urogynecologists...
Canada Food, Drugs, Healthcare, Life Sciences

Health Canada released a Dear Health Professional Letter on December 15, 2020 to advise healthcare professionals, including urologists, urogynecologists, ophthalmologists, optometrists, family physicians, and pharmacists about cases of pigmentary maculopathy reported with use of Elmiron.

As discussed in our previous post Elmiron is a medication prescribed to treat interstitial cystitis and has been linked to vision loss.

Cases of pigmentary maculopathy, which involves changes to the retina that can cause vision loss and impairment, have been reported with Elmiron usage. Individuals who have used Elmiron for three years or longer are particularly at risk.

The Health Canada publication advises healthcare professionals of the risk of pigmentary maculopathy with Elmiron and contraindicates the drug in patients with a history of macular disease.

The Canadian Product Monograph for Elmiron has been updated to include the contraindication and to provide information about the risk of pigmentary maculopathy.

Siskinds LLP has commenced class proceedings on behalf of Canadians that have suffered vision impairment related to the usage of Elmiron. Siskinds LLP is available and willing to review and discuss your potential case. If you or a loved one has suffered vision impairment or injury following usage of Elmiron, please contact our medical product liability team for the class action here.

Originally Published by Siskinds, December 2020

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Find out more and explore further thought leadership around Food, Drugs, Healthcare, Life Sciences

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More